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Abstract 
Purpose: Differentiated thyroid cancer (DTC) accounts for approximately 95% of thyroid 
carcinomas. In the metastatic RAI-refractory disease, chemotherapy has very limited efficacy and is 
associated with substantial toxicity. With increasing knowledge of the molecular pathogenesis of 
DTC, novel targeted therapies have been developed. Lenvatinib is a tyrosine kinase inhibitor (TKI) 
with promising clinical activity based on the randomized phase III SELECT trial. In Switzerland, a 
Named Patient Program (NPP) was installed to bridge the time gap to Swissmedic approval. Here, 
we report the results from the Swiss Lenvatinib NPP including patients with metastatic 
RAI-refractory DTC.  
Methods: Main inclusion criteria for the Swiss NPP were RAI-refractory DTC, documented disease 
progression, Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The number 
of previous therapies was not limited. The Swiss Lenvatinib NPP was initiated in June 2014 and was 
closed in October 2015 with the approval of the drug. 
Results: Between June 2014 and October 2015, 13 patients with a median age of 72 years have been 
enrolled. Most patients (69%) had at least one prior systemic therapy, mainly sorafenib. 31% of 
patients showed a PR and 31% SD. Median progression free survival was 7.2 months and the median 
overall survival was 22.7 months. Dose reduction due to adverse events was necessary in 7 patients 
(53%). At the time of analysis 6 patients (47%) were still on treatment with a median time on 
treatment of 9.98 months.  
Conclusions: Our results show that lenvatinib has reasonable clinical activity in unselected patients 
with RAI-refractory thyroid cancer with nearly two-third of patients showing clinical benefit. The 
toxicity profile of lenvatinib is manageable. 
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Introduction 
Differentiated thyroid cancer (DTC) accounts for 
approximately 95% of thyroid carcinomas and arises 
from aberrant follicular cells. It is histologically 
classified as either papillary, follicular (including 
Hurthle cell), or poorly differentiated. DTC is the 
most common endocrine malignancy, and its 
incidence from 3,6 per 100’000 in 1973 to 8,7 per 
1000’000 in 2002 in the United States [1]. Although 
most patients with this disease have an excellent 
prognosis, some suffer from an aggressive, refractory 
form. Generally, localized DTC is effectively treated 
by surgery, radioactive iodine (RAI), and suppressive 
thyroid hormone therapy [2]. Up to one quarter of 
patients with DTC develop distant metastases and 
two third of patients with distant metastases will 
eventually become RAI-refractory [3, 4]. Until recently 
the only systemic therapy approved by the American 
Food and Drug Administration (FDA) for these 
patients was doxorubicin [5]. However, doxorubicin 
alone or in combination with other cytotoxic agents 
such as cisplatin has very limited efficacy and is 
associated with substantial toxicity including cardiac 
and hematologic adverse events. With increasing 
knowledge of the molecular pathogenesis of DTC, 
novel targeted therapies have been developed. 
Clinical trials investigated tyrosine kinase inhibitors 
(TKIs) interacting with the main signalling cascades 
important in the pathogenesis of DTC. Sorafenib is an 
orally active inhibitor of VEGF receptor - 3 and Raf 
kinases. In the randomized phase III DECISION trial a 
total of 417 patients with locally advanced or 
metastatic RAI-refractory DTC and disease 
progression within the past 14 months were randomly 
assigned to receive 400 mg of oral sorafenib twice 
daily or matching placebo[6]. Patients receiving 
placebo were allowed to receive open-label sorafenib 
upon disease progression. Sorafenib extended the 
median progression-free survival (PFS) from 5.8 to 
10.8 months (Hazard ratio (HR) 0.59, 95% confidence 
interval (CI) 0.45-0.76, p<0.0001). Overall survival 
(OS) was statistically not different most likely due to 
the high rate (71,4%) of cross-over from placebo to 
sorafenib at disease progression. Based on these data, 
sorafenib is licenced for treatment of RAI-refractory 
DTC in many countries worldwide. 
Lenvatinib is another TKI targeting VEGFR1-3, 
FGFR1-4, PDGFR-b, RET, and c-KIT. Phase II trials in 
advanced thyroid cancer documented response rates 
of up to 50% and provided the rationale for a 
subsequent randomized, placebo-controlled phase III 
trial [7, 8]. The phase III randomized, double-blind, 
multicentre SELECT trial included 392 patients with 
RAI-refractory progressive DTC [9]. Patients were 
randomized in a 2:1 fashion lenvatinib (24 mg daily) 
or matching placebo. The median PFS was 18.3 
months with lenvatinib vs. 3.6 month in the placebo 
group (HR 0.21, 99% CI 0.14-0.31, p<0.001). The PFS 
benefit was statistically significant among all 
subgroups including patients previously treated with 
another TKI what was the case for 66 (25.3%) patients 
in the lenvatinib arm and 27 (20.6%) patients in the 
placebo arm. The clinical benefit was independent of 
distinct histological (i.e. papillary, poorly 
differentiated, follicular, and Hurthle cell) and 
molecular subtype (BRAF and RAS mutational 
status). In Switzerland, a Named Patient Program 
(NPP) was initiated to provide lenvatinib upon 
physician request on compassionate basis for eligible 
patients.  
At this time, sorafenib was already approved 
and reimbursed in Switzerland. The question of 
sequencing both TKIs and their use in daily clinical 
practice outside clinical trials has yet not been 
investigated. Here, we report the results from the 
Swiss Lenvatinib NPP for patients with metastatic 
RAI-refractory DTC.  
Patients and Methods 
Main inclusion criteria for the Swiss NPP were 
RAI-refractory DTC, documented disease 
progression, Eastern Cooperative Oncology Group 
(ECOG) performance status 0-2. The number of 
previous therapies was not limited. Lenvatinib was 
provided by Eisai Pharma Switzerland. All patients 
received at least one dose. Therapy was initiated with 
a dose of 24 mg in all patients. Dose reduction upon 
toxicity assessment was at the discretion of the local 
investigator. Treatment was supposed to be continued 
until disease progression, clinical deterioration 
and/or unacceptable toxicities or until death. The 
Swiss Lenvatinib NPP was initiated in June 2014 and 
was closed in October 2015 with the approval of 
lenvatinib in Switzerland.  
Patient- and tumor-specific data were obtained 
from the patients’ medical records. Imaging studies 
were performed at the discretion of the treating 
physician. Patients were followed for disease 
progression and survival until December 2015. 
Overall response rate (ORR) was defined 
according to Response Evaluation Criteria In Solid 
Tumors (RECIST) criteria version 1.1[10]. If available 
we also report thyroglobulin levels before and under 
therapy. PFS was calculated from beginning of 
therapy to the first date of confirmed tumor 
progression, death or the date of last follow-up. 
Progression was defined as clinical and/or 
radiographic progression. OS was calculated from 
beginning of lenvatinib therapy of metastatic 
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RAI-refractory disease to patients’ death or date of 
last follow-up.  
Objectives 
The overall objective of this retrospective 
analysis was to evaluate the outcome of patients with 
metastatic DTC undergoing treatment with 
lenvatinib. The primary objective was to assess overall 
survival in patients with RAI-refractory DTC 
included in the Swiss Lenvatinib NPP. Secondary 
objectives included response rate, PFS and toxicity.  
Ethical considerations 
The respective local ethics committees approved 
implementation of the NPP. This retrospective data 
collection was approved by the ethics committee 
North-Western and Central Switzerland (EKNZ; 
2015-364) as well as by the respective local ethics 
committees of participating centers. 
Statistical methods 
Numerical data are described with median, 
mean, standard deviation, quartiles and percentages 
as appropriate. PFS and OS were evaluated using 
Kaplan-Meier estimates with 95% confidence intervals 
(CI). PFS was defined as duration between the 
beginning of lenvatinib therapy until disease 
progression or death. OS was calculated from 
beginning of lenvatinib therapy of metastatic 
RAI-refractory disease to patients’ death or date of 
last follow-up. All statistical analyses were performed 
with IBM SPSS Statistics software version 22 (IBM 
Corporation, New York, USA) and Excel Microsoft. 
Results 
Patients 
Between June 2014 and October 2015, 13 patients 
have been enrolled in 8 different hospitals in 
Switzerland. From all these patient records were 
accessible and all 13 patients were considered for 
efficacy analysis. Patient- and tumor-specific 
characteristics are summarized in Table 1. Median age 
at the time of diagnosis was 61 years (Interquartile 
range (IQR) ±20.7) and at the time of inclusion in the 
NPP median age was 72 years (IQR ±16.8). All 
patients have previously been undergone by 
thyroidectomy and 11 patients (85%) had received 
postoperative radio-iodine therapy. At inclusion in 
the NPP, 12 patients (92%) had lung metastases and 9 
patients (69%) had bone metastases. Median duration 
between RAI-refractory status and start of lenvatinib 
was 48 months.  
Previous therapy 
Most patients had one prior systemic therapy. 8 
patients (62%) were previously treated with sorafenib. 
2 patients (15%) had a previous chemotherapy with 
docetaxel, cisplatin, 5-fluorouracil (TCF) and one 
patient (8%) was treated with cisplatin and 
doxorubicin. One patient previously treated with 
chemotherapy and sorafenib also received pazopanib 
and vandetanib. Another patient was pretreated with 
sorafenib and pazopanib. For 4 patients (23%) 
lenvatinib was the first systemic therapy.  
 
Table 1. Baseline Characteristics 
 All patients (N=13) 
Age at time of analysis (years) –Median (Range) 72 (37-81) 
Age at Diagnosis (years) –Median (Range) 61 (30-77) 
Duration from RAI-refractory disease up to the 
beginning of a therapy in (months) – Median (Range) 
48 (2-96) 
Sites of Metastasis Median Number (Range) 1 (0-4) 
Lung 12 
Bone 9 
Lymph nodes 4 
Soft tissue 2 
Liver 2 
Brain 2 
Heart 1 
Previous systemic treatment before Lenvatinib 
Median Number (Range) 
1 (0-4) 
Sorafenib  8  
Pazopanib 1  
Vandetanib 1  
Chemotherapy (Cisplatin/Doxorubicin or TCF) 2  
None 4  
 
Efficacy  
4 patients (31%) reached partial response (PR) 
and 4 additional patients (31%) stable disease (SD) 
(Table 2). In summary, disease control rate (DCR) was 
62%. Out of 8 patients with disease control under 
lenvatinib therapy 4 had documented bone 
metastases at the time of treatment initiation. At the 
time of analysis, 7 patients (53%) had stopped 
treatment with lenvatinib. Two patients (15%) died 
due to disease progression and 3 patients (23%) 
stopped therapy due to drug toxicity. For two 
patients, the reason for treatment discontinuation was 
unclear. So far, the longest treatment duration was 18 
months and is still receiving lenvatinib at a dose of 14 
mg per day. Overall, the estimated median PFS was 
7.2 months (95% CI, 0.78-13.67) (Figure 1). The 
estimated median OS was 22.7 months (95% CI 0-53.9) 
(Figure 2).  
Thyroglobulin levels 
6 patients had serial determination of serum 
thyroglobulin levels. Five patients (83%) had a 
response and showed a decrease in thyroglobulin 
levels correlating with the radiologic response 
(Figure 3).  
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Table 2. Clinical Outcome 
 All patients (N=13) 
Best response on lenvatinib (N)  
Complete response 0 
Partial response 4 
Stable disease 4 
Progressive disease 1 
not evaluable 4 
Duration of lenvatinib treatment (months) – median 
(range) 
5 (1-18+) 
Ongoing (N) 6 
Terminated (N) 7 
 
 
 
 
Figure 1. Progression-free survival for lenvatinib therapy 
 
 
Toxicity 
In general, side effects were very common, 12 of 
13 patients had at least one adverse event (AE). 7 
patients (54%) had a grade 3 or 4 (G3/4) AEs. The 
most common AEs were fatigue (46%), diarrhoea 
(30%) and stomatitis (30%) (Table 3). The most 
common severe (G3/4) adverse events were fatigue, 
hypertension, acute pancreatitis, neutropenia, 
mucositis/stomatitis, and diarrhoea. There were no 
unexpected AEs when compared to the published 
literature. Generally, side effects were manageable; 7 
patients (53%) had a dose reduction in the course of 
lenvatinib therapy (6 patients to 14 mg per day and 
one to 10 mg per day). All patients started with the 
recommended dose of 24 mg daily. Lenvatinib dose 
was reduced after a median treatment time of 162 
days. 3 patients had to discontinue due to toxicity. 
Reasons for discontinuation in these 3 patients were 
proteinuria, oral ulcers, and acute pancreatitis.  
 
 
Figure 2. Overall survival from beginning of lenvatinib therapy 
 
 
Figure 3. Thyroglobulin levels in the serum.  
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Table 3. Toxicity 
 Total number of patients (N=13) 
All grade, N Grade 1-2, N Grade 3-4, N 
Any AE 12 3 9 
Diarrhea 4 2 2 
Constipation 3 2 1 
Fatigue 6 4 2 
Stomatitis/Mucositis 4 3 1 
Dyspnea 1 1 0 
Dysphonia 1 1 0 
Exanthema 2 2 0 
Acute Pancreatitis 1 0 1 
Hypertension 2 1 1 
Anorexia 3 2 1 
Nausea 1 1 0 
Hand-Foot-Syndrome 1 1 0 
Proteinuria 1 0 1 
Haematotoxicity 1 0 1 
Angina pectoris 1 1 0 
 
Discussion 
In this retrospective analysis of the Swiss 
Lenvatinib NPP, we were able to collect 
comprehensive clinical data including sequential 
thyroglobulin levels from 13 unselected patients 
included in this program. Compared to the pivotal 
SELECT study [9] of lenvatinib in RAI-refractory DTC 
with a response rate of 64.8% and a median PFS time 
of 18.3 months, our results are clearly inferior. 
However, our patients had a more advanced disease 
setting compared to those in the SELECT trial. In the 
Swiss Lenvatinib NPP 69% of patients had bone 
metastases, a known negative prognostic factor. This 
rate was only 40% in the SELECT trial. In the SELECT 
trial only 25% of patients were previously treated 
with another systemic therapy for RAI-refractory 
disease. In our retrospective analysis patients had 
received up to 4 previous treatment lines including 
TKIs and chemotherapy. Most importantly, 62% of 
our patients had previous therapy with sorafenib. 
Nevertheless, 62% of patients treated with lenvatinib 
showed a clinical benefit and 31% had a documented 
response. The median PFS of 7.2 months is substantial 
for this advanced and heavily pretreated patient 
population.  
Absolute thyroglobulin levels have been mainly 
studied as a prognostic factor for recurrence and 
survival in DTC [11, 12]. The role of monitoring of 
thyroglobulin in patients with advanced DTC during 
treatment with anti-angiogenic drugs is not well 
established. In the DECISION trial changes in 
thyroglobulin concentrations correspond to 
radiographic response [6]. Despite the small number 
of patients with consecutive thyroglobulin 
concentration measurement in our study, we also see 
a correlation to radiographic response supporting the 
hypothesis that serum thyroglobulin determination 
can be used on an individual basis to monitor 
treatment with TKIs. 
More than 50% of patients needed a dose 
reduction, but could be treated over long time with a 
good toxicity management. One patient had an 18 
months lenvatinib exposition and is still ongoing, 
although at a reduced dosage. 
In a recent meta-analysis the relationship 
between toxicities and clinical benefits of lenvatinib 
and sorafenib in patients with DTC has been analysed 
[11]. The toxicity rate was similar to our analysis. 
However, adverse events usually seem manageable 
and lenvatinib was associated with clinical benefit 
when considering adverse events. Another 
meta-analysis focussing on AEs of lenvatinib reported 
in the 14 currently published clinical trials reported 
involved a total number of 978 patients 
predominantly with thyroid cancer and renal cell 
carcinoma [12]. The most frequent grade ≥3 
treatment-related adverse events were 
thrombocytopenia, hypertension, peripheral edema 
and increased aspartate aminotransferase levels.  
Current guidelines from the American Thyroid 
Association list lenvatinib as one possible systemic 
treatment option for RAI-refractory DTC [2]. The 
knowledge of its toxicity profile should prompt 
considerable restraint in the use of kinase inhibitors 
(e.g. lenvatinib) in patients with stable or slowly 
progressive disease who likely have a disease-specific 
mortality that may also be low over the following 
years. Interestingly, the median time delay from 
initial diagnosis of DTC until inclusion in the Swiss 
Lenvatinib NPP was 11 years and the median time for 
diagnosis of RAI-refractory disease to start of 
lenvatinib was 4 years. This finding confirms the 
generally slow growing of the disease. Therefore, one 
of the most important questions in the treatment of 
RAI-refractory DTC is which patients are in need of a 
systemic therapy. These patients often survive for a 
long time, and in many cases, their quality of life is 
very good. For this reason, only patients with an 
advanced and progressive disease should undergo a 
treatment with targeted therapies. According to 
expert opinion [13], good candidates are patients with 
a RAI-refractory metastatic thyroid cancer with 
radiographic measurable lesions that have been in 
progression over the previous 12–14 months, as 
defined by RECIST criteria. 
Our study has several limitations. The 
retrospective design, the small sample size and the 
broad heterogeneity of the patient population are the 
most relevant factors. However, this is to our best 
knowledge the first report on real life experience with 
lenvatinib in patients with RAI-refractory DTC 
patients after the report of the randomized phase III 
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SELECT trial [9]. Therefore, we think that these data 
are of relevance with regard to the feasibility and the 
efficacy of lenvatinib in DTC patients. Furthermore, 
we show that the toxicity profile of this drug is 
generally manageable.  
In conclusion, lenvatinib has clinically 
meaningful benefits in patients with RAI-refractory 
DTC. It is important to closely follow-up patients 
during therapy, to establish comprehensive toxicity 
management guidelines and to consider dose 
reduction in patients with higher-grade toxicities. 
Patients should be instructed to report any side effects 
as early as possible to allow a prompt management. 
Providing good information and good 
communication with doctors and/or dedicated nurses 
is the best way to help patients during this therapeutic 
program [14]. 
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